8-K/A: Skye Bioscience Corrects Stock Option Share Count
Amendment to Current Report
Skye Bioscience files an amendment to a previous 8-K report to correct a clerical error regarding the total number of shares underlying repriced stock options.
Summary
- Skye Bioscience, Inc. has filed an amendment (Form 8-K/A) to a previous report dated April 3, 2026.
- The amendment corrects a scrivener's error concerning the total number of common stock shares underlying all 'Repriced Options'.
- The corrected total number of shares underlying these Repriced Options is 2,458,158.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it is a procedural correction of a clerical error without new financial or strategic information.
Future Outlook
No specific forward-looking statements or guidance were provided in this amendment.
Industry Context
StockSavvy.ai notes that this filing is a procedural correction of a prior disclosure, indicating a focus on accurate reporting of equity compensation details, which is a common area of scrutiny in the biotechnology sector.
Stakeholder Impact
- Shareholders: The correction clarifies the exact number of shares underlying repriced options, providing greater transparency regarding potential future dilution.
Key Dates
| Date | Description |
|---|---|
| March 31, 2026 | Date of earliest event reported |
| April 3, 2026 | Date of Original Report (Form 8-K) |
| April 6, 2026 | Date of filing the Amendment (Form 8-K/A) |
Keywords
Skye Bioscience, 8-K/A, Stock Options, Share Count, SEC Filing, Amendment, Corporate Disclosure
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.